Profitelligence Profitelligence · Filing Ledger Open BSX research →

Form 8-K · Current Report · Filed 2024-05-10

Boston Scientific Appoints Dr. Cheryl Pegus to Board of Directors

Boston Scientific Corporation announced on May 8, 2024, the election of Dr.

Filer
Boston Scientific Corporation BSX · NYSE
Filed
Accession
0000885725-24-000050
CIK
0000885725
Signal
High impactHealthcare

Details

Cheryl Pegus to its board of directors, effective immediately. Dr. Pegus, a highly respected clinical leader, will contribute to the company's growth and patient care. Additionally, on May 9, 2024, the company amended its By-Laws for administrative changes. The board also approved a third amendment to its $2.750 billion revolving credit agreement, extending the maturity date to May 10, 2029. These events were disclosed via a press release on May 8, 2024.

Items reported

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

New CEO Appointed Board Member Appointed
Item 5.03

Amendments to Articles of Incorporation or Bylaws

Bylaw Amendment
Item 7.01

Regulation FD Disclosure

Regulation FD Disclosure
Item 8.01

Other Events

Regulatory Approval Regulatory Denial

Market reaction

Close before filing

$74.10

Next session

-1.7%

Since filing

-36.9%

Latest close

$46.73

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from BSX reporting the same item, with the next session's move:

Exhibits (4)

About Boston Scientific Corporation

Boston Scientific Corporation, a leading global medical device company, is renowned for developing and supplying innovative health solutions. Its primary function is to design, manufacture, and market medical devices used in interventional medical specialties such as cardiology, peripheral interventions, cardiac rhythm management, endoscopy, urology, and neuromodulation. The company's product offerings significantly impact sectors like health care, particularly those focusing on minimally invasive treatments. Boston Scientific's products help improve the quality of patient care and reduce the need for major surgery, thus playing a crucial role in modern healthcare systems. Their devices contribute to procedures that are less invasive, more effective, and often more economic, supporting better patient outcomes and quicker recovery times. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific provides its products to healthcare providers and institutions worldwide. In the financial markets, Boston Scientific Corporation holds significant influence as a major player in the healthcare industry, contributing to advancements in medical technology and shaping the future of patient care through research and development. Its presence underscores the importance of innovation in medical devices and its role in enhancing healthcare delivery.

Exchange NYSE Industry Medical Devices Company website ↗

Never miss another BSX filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts